Growth Hormone Secretion
Tesamorelin
TH9507; Egrifta
GHRH analog (FDA-approved)
This Tesamorelin entry draws on 13 cited sources published 2007 to 2026. The evidence available is graded FDA-Approved on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- GHRH analog (FDA-approved)
- Drug class
- Growth Hormone Secretion
- Structure
- 44-aa GHRH(1-44) analog with N-terminal trans-3-hexenoyl; MW ~5135 Da
- Route
- SC injection
- Half-life
- ~26 min
- Evidence tier
- FDA-Approved
- Availability
- Prescription
- Research depth
- 169 indexed citations →
Mechanism of action
Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion
Reported areas of research
Reduces visceral abdominal fat (HIV lipodystrophy); lowers triglycerides; modest IGF-1 rise
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
2 mg SC daily (FDA label)
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1
Compared with
Tesamorelin has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for Tesamorelin in research literature?
Published peptide research reports the following dosing approach for Tesamorelin: 2 mg SC daily (FDA label). This is a research reference, not a clinical recommendation.
How is Tesamorelin administered in research?
Tesamorelin is administered via the following routes in published studies: SC injection.
What is the reported half-life of Tesamorelin?
The reported half-life of Tesamorelin is ~26 min.
Is Tesamorelin FDA-approved?
Yes. Tesamorelin is an FDA-approved drug. PeptideHelper.org catalog status: Prescription.
What level of evidence supports Tesamorelin?
The current evidence base for Tesamorelin is best characterised as: FDA-Approved. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Tesamorelin?
Known concerns reported in the literature for Tesamorelin include: Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1. Always consult a qualified clinician before any human use.
Is there anyone who should not use Tesamorelin?
Yes. The FDA label for EGRIFTA SV lists formal contraindications for Tesamorelin: EGRIFTA SV is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis Patients with active malignancy Patients with known hypersensitivity to tesamorelin or excipients in EGRIFTA SV Pregnancy EGRIFTA SV is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma. Patients with active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy. Patients with known hypersensitivity to tesamorelin or the excipients in EGRIFTA SV. Pregnant women because modifying visceral adipose tissue offers no benefit in a pregnant woman and could result in fetal harm. This is the label's own wording, quoted rather than paraphrased. Always consult a qualified clinician before any human use.
How does Tesamorelin work?
The mechanism of action reported for Tesamorelin in the literature: Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion.
What is Tesamorelin studied for?
Tesamorelin has been studied in the published literature for: Reduces visceral abdominal fat (HIV lipodystrophy); lowers triglycerides; modest IGF-1 rise. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Tesamorelin?
Tesamorelin is classified as: GHRH analog (FDA-approved). Also known as: TH9507; Egrifta.
Studied in combination
Tesamorelin appears in the following peptide combinations discussed in research and practitioner literature:
- Fat Loss GH, Visceral fat reduction + GH pulse
Combinations to avoid
Tesamorelin appears in 1 flagged combination catalogued on PeptideHelper.org:
- Two GHRHs in the same regimen, Moderate risk per peptide research literature.
Drug class
- GHRH peptides, see all peptides tagged GHRH.
- GH-secretagogue peptides, see all peptides tagged GH-secretagogue.
Research focus area
All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.
Primary sources
- FDA Egrifta SV (tesamorelin) prescribing information
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
- Stanley TL et al. Reduction in visceral adiposity with tesamorelin and improved metabolic profile in HIV-infected patients. Clin Infect Dis 2012. PMID 22495074
- Erlandson KM et al. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ open 2026. PMID 42419889
- Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology 2026. PMID 42395176
- Stewart CE et al. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci 2026. PMID 42382101
- Villegas Meza AD et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews 2026. PMID 42160466
- Beach R et al. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026. PMID 42139091
- Renke G et al. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International journal of molecular sciences 2026. PMID 42123471
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.) 2026. PMID 41966639
- Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury [NCT03150511 PHASE2 RECRUITING]
- Colpaert T et al. Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS. Drug testing and analysis 2026. PMID 43013893
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease [NCT07481734 PHASE2 RECRUITING]
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…